The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

Haemophilia

Volumn 22, Issue 4, 2016, Pages 487-498

  Collins, P ^a   Chalmers, E ^b   Chowdary, P ^c   Keeling, D ^d   Mathias, M ^e   O'Donnell, J ^f   Pasi, K J ^g   Rangarajan, S ^h   Thomas, A ⁱ  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f ST JAMES S HOSPITAL   (Ireland)

^g ROYAL LONDON HOSPITAL   (United Kingdom)

^h BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

ⁱ ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

coagulation factor concentrates; enhanced half life; pharmacokinetics; prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

BLEEDING; CHEMICAL MODIFICATION; CHILD HEALTH CARE; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSULTATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR SURGERY; MINIMUM PLASMA CONCENTRATION; MINOR SURGERY; NONHUMAN; PEGYLATION; PHARMACOKINETIC ASSAY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 84979083925     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13013     Document Type: Review

References (50)

1. Carcao M. Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit? Haemophilia 2015; 21: 297–9.
2. Croteau SE, Neufeld EJ. Transition considerations for extended half-life factor products. Haemophilia 2015; 21: 285–8.
3. Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015; 169: 768–76.
4. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87: S33–9.
5. Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015; 13: S176–9.
6. Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270–9.
7. Ostergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333–41.
8. Stennicke HR, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108–16.
9. Turecek PL, Bossard MJ, Graninger M et al. BAX 855, a PEGylated rFVIII product with prolonged half-life: development, functional and structural characterisation. Hamostaseologie 2012; 32: S29–38.
10. Metzner HJ, Pipe SW, Weimer T, Schulte S. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost 2013; 110: 931–9.
11. Peters RT, Low SC, Kamphaus GD et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057–64.
12. Peters RT, Toby G, Lu Q et al. Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost 2013; 11: 132–41.
13. Rath T, Baker K, Dumont JA et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2015; 35: 235–54.
14. Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488–96.
15. Konkle BA, Stasyshyn O, Chowdary P et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126: 1078–85.
16. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317–25.
17. Powell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031–7.
18. Tiede A, Brand B, Fischer R et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670–8.
19. Collins PW, Young G, Knobe K et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880–6.
20. Martinowitz U, Lissitchkov T, Lubetsky A et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 2015; 21: 784–90.
21. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695–701.
22. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313–23.
23. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–11.
24. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666–72.
25. Carcao M, Zak M, Karim FA et al. Nonacog Beta Pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated paediatric haemophilia B patients. Haemophilia 2015; 21: 28.
26. Fischer K, Kulkarni R, Nolan B et al. Safety, efficacy and pharmacokinetics of recombinant factor IX FC fusion protein in children with haemophilia B (KIDS B-Long). J Thromb Haemost 2015; 13: LB009.
27. Young G, Mahlangu J, Kulkarni R et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13: 967–77.
28. Hay CRM, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367–70.
29. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160: 153–70.
30. Bjorkman S, Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180–2.
31. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.
32. Powell J, Shapiro A, Ragni M et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol 2015; 168: 113–23.
33. Boggio LN, Hong W, Wang M, Eyster E, Michaels LE. Bleeding phenotype with various Bay94-9027 dosing regimens: subanalyses from the Protect VIII Study. Blood 2014; 1526 ASH abstract book.
34. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2–10.
35. Richards M, Williams M, Chalmers E et al. A United Kingdom haemophilia centre doctors' organization guideline approved by the British committee for standards in haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498–507.
36. Santagostino E, Jacobs I, Voigt C. Pharmacokinetic results of two phase III clinical studies of coagulation factor IX (recombinant) albumin fusion protein (rIX-FP) in previously treated patients with hemophilia B (Prolong-9FP). Haemophilia 2015; 21(Suppl. 2): 27 Poster PP026.
37. Chowdary P, Dunkley S, Enhrenforth S et al. First report on the safety and efficacy of a long-acting recombinant factor VIII (turoctocog alfa pegol, N8-GP) during major surgery in patients with severe hemophilia A. Blood 2015; 2283 ASH abstract book.
38. Escobar M, Colberg T, Karim FA et al. Perioperative hemostatic management of major surgery in hemophilia B with long acting recombinant long-acting glycopegylated factor IX: results from the Paradigm 3 clinical trial. J Thromb Haemost 2015; 13: 229.
39. Powell JS, Apte S, Chambost H et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2015; 168: 124–34.
40. Negrier C, Lapatan LM, Lubetsky A et al. Efficacy and safety of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B undergoing a surgical procedure. J Thromb Haemost 2015; 13(Suppl. 2): 843.
41. Hubbard AR, Dodt J, Lee T et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11: 988–9.
42. Dodt J, Hubbard AR, Wicks SJ et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
43. Sommer JM, Moore N, Mcguffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
44. Gu JM, Ramsey P, Evans V et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20: 593–600.
45. Sommer JM, Buyue Y, Bardan S et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost 2014; 112: 932–40.
46. Sorensen MH, Andersen S, Ezban M. Factor IX-deficient plasma spiked with N9-GP behaves similarly to N9-GP post-administration clinical samples in N9-GP ELISA and FIX activity assays. Haemophilia 2015; 21: 832–6.
47. European Medicines Agency. CHMP Safety Working Party's response to the PDCO regarding the use of PEGylated drug products in the paediatric population. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/11/WC500135123.pdf 2012. Accessed May 25, 2016.
48. Giangrande P, Chowdary P, Enhrenforth S et al. Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocg alfa pegol, N8-GP): efficacy and safety in previously treated patients with severe hemophilia A – results of pathfinder2 international trial. J Thromb Haemost 2015; 13: OR212.
49. Santagostino E, Martinowitz U, Lissitchkov T et al., Long acting recombinant coagulation factor IX albumin fusion (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016; 127: 1761–9.
50. Kenet G, Chambost H, Male C et al. Efficacy, pharmacokinetics (PK) and safety results of a phase III clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated children with hemophilia B. J Thromb Haemost 2015; 13(Suppl. 2): O346.